US 11,939,384 B1
Antibody variable domains targeting the NKG2D receptor
Gregory P. Chang, Medford, MA (US); Ann F. Cheung, Lincoln, MA (US); Asya Grinberg, Lexington, MA (US); William Haney, Wayland, MA (US); Bradley M. Lunde, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Dragonfly Therapeutics, Inc., Waltham, MA (US)
Filed by Dragonfly Therapeutics, Inc., Waltham, MA (US)
Filed on Nov. 3, 2023, as Appl. No. 18/501,413.
Application 18/501,413 is a division of application No. 16/967,216, previously published as PCT/US2019/017330, filed on Feb. 8, 2019.
Claims priority of provisional application 62/716,259, filed on Aug. 8, 2018.
Claims priority of provisional application 62/628,161, filed on Feb. 8, 2018.
Int. Cl. A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/00 (2006.01)
CPC C07K 16/2851 (2013.01) [C07K 16/2803 (2013.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 16 Claims
 
1. A method of providing a cancer immunotherapy for treating a cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of a protein comprising an antigen-binding site that binds NKG2D and an additional antigen-binding site that binds a tumor-associated antigen expressed by the cancer,
wherein the antigen-binding site that binds NKG2D comprises:
an antibody heavy chain variable domain comprising a complementarity-determining region 1 (CDR1) amino acid sequence of SEQ ID NO: 48, a complementarity-determining region 2 (CDR2) amino acid sequence of SEQ ID NO: 30, and a complementarity-determining region 3 (CDR3) amino acid sequence of SEQ ID NO: 78, 74, 76, 80, or 82; and
an antibody light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO: 32, a CDR2 amino acid sequence of SEQ ID NO: 33, and a CDR3 amino acid sequence of SEQ ID NO: 34,
wherein the additional antigen-binding site comprises an antibody heavy chain variable domain,
wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D is present on a first polypeptide that further comprises a first antibody constant region, and the antibody heavy chain variable domain of the additional antigen-binding site is present on a second polypeptide that further comprises a second antibody constant region, and
wherein the first antibody constant region and the second antibody constant region form a complex that binds CD16.